Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-alpha
We evaluated density of the natural killer (NK) cell-associated CD56 antigen on circulating NK cells of 47 patients with advanced renal cell carcinoma. Patients received a combination of low-dose subcutaneous recombinant interleukin-2 (rIL-2) and recombinant interferon-alpha (rIFN-alpha) as home therapy. Antigen density of CD56 before therapy was 2.2-fold higher (P < 0.005) in patients who subsequently achieved a complete or partial remission when compared with patients who presented with progressive disease on therapy. After a 6-week treatment cycle, NK cells of treatment responders expressed significantly (2.1-fold; P < 0.005) more CD56 antigens than NK cells in nonresponding patients. These results suggested a potential role of both pre- and posttreatment NK antigen density levels as a biologic correlate to treatment response.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1992 |
|---|---|
| Erschienen: |
1992 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Clonal identification of Burkitt's lymphoma arising from lymphocyte-predominant Hodgkin's disease - 4(1992), 4 vom: 30. Dez., Seite 170-3 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Duensing, S [VerfasserIn] |
|---|
| Themen: |
Antigens, CD |
|---|
| Anmerkungen: |
Date Completed 10.02.1993 Date Revised 16.11.2017 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM012626937 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM012626937 | ||
| 003 | DE-627 | ||
| 005 | 20231221053122.0 | ||
| 007 | tu | ||
| 008 | 231221s1992 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0042.xml |
| 035 | |a (DE-627)NLM012626937 | ||
| 035 | |a (NLM)1282326 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Duensing, S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-alpha |
| 264 | 1 | |c 1992 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 10.02.1993 | ||
| 500 | |a Date Revised 16.11.2017 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a We evaluated density of the natural killer (NK) cell-associated CD56 antigen on circulating NK cells of 47 patients with advanced renal cell carcinoma. Patients received a combination of low-dose subcutaneous recombinant interleukin-2 (rIL-2) and recombinant interferon-alpha (rIFN-alpha) as home therapy. Antigen density of CD56 before therapy was 2.2-fold higher (P < 0.005) in patients who subsequently achieved a complete or partial remission when compared with patients who presented with progressive disease on therapy. After a 6-week treatment cycle, NK cells of treatment responders expressed significantly (2.1-fold; P < 0.005) more CD56 antigens than NK cells in nonresponding patients. These results suggested a potential role of both pre- and posttreatment NK antigen density levels as a biologic correlate to treatment response | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antigens, CD |2 NLM | |
| 650 | 7 | |a Antigens, Differentiation, T-Lymphocyte |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a CD56 Antigen |2 NLM | |
| 650 | 7 | |a Interferon-alpha |2 NLM | |
| 650 | 7 | |a Interleukin-2 |2 NLM | |
| 650 | 7 | |a Recombinant Proteins |2 NLM | |
| 700 | 1 | |a Hadam, M |e verfasserin |4 aut | |
| 700 | 1 | |a Körfer, A |e verfasserin |4 aut | |
| 700 | 1 | |a Schomburg, A |e verfasserin |4 aut | |
| 700 | 1 | |a Menzel, T |e verfasserin |4 aut | |
| 700 | 1 | |a Grosse, J |e verfasserin |4 aut | |
| 700 | 1 | |a Kirchner, H |e verfasserin |4 aut | |
| 700 | 1 | |a Poliwoda, H |e verfasserin |4 aut | |
| 700 | 1 | |a Atzpodien, J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |a Yoshinaga, H |t Clonal identification of Burkitt's lymphoma arising from lymphocyte-predominant Hodgkin's disease |d 1996 |g 4(1992), 4 vom: 30. Dez., Seite 170-3 |w (DE-627)NLM012626929 |
| 773 | 1 | 8 | |g volume:4 |g year:1992 |g number:4 |g day:30 |g month:12 |g pages:170-3 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 1992 |e 4 |b 30 |c 12 |h 170-3 | ||